

| Date   | Time             | Track                                    | Presentation Title   | Speaker   |
|--------|------------------|--|--|---|
| 27-Feb | 06:00 - 07:00 AM | Effective Tools for Drug Development     | Biomarkers of Aging  | Alex Zhavoronkov, PhD<br>Founder and CEO, Insilico Medicine, Inc.   |
| 27-Feb | 06:00 - 07:00 AM | Effective Tools for Drug Development     | Discovering Cellular Mechanisms and Biomarkers in Anti-PD1 Non-Responders Using Ingenuity Pathway Analysis Software and OmicSoft OncoLand Datasets from QIAGEN | Devendra Mistry, PhD<br>Senior Field Application Scientist, QIAGEN Advanced Genomics  |
| 27-Feb | 06:00 - 07:00 AM | Effective Tools for Drug Development     | Keynote Presentation: Reimagining Drug Discovery and Development Journey Through AI  | Szczepan Baran, VMD, MS<br>Head of Emerging Technologies, LAS, Novartis   |
| 27-Feb | 06:00 - 07:00 AM | Effective Tools for Drug Development     | The Missing Link to Improving Efficiency and Productivity in the Digital Lab   | Jay Campbell<br>Chief Commercial Officer, Somark Innovations  |
| 27-Feb | 07:30 - 08:30 AM | Novel Strategies for Drug Discovery      | Keynote Presentation: Second Harmonic Generation Detection of Ras Conformational Changes and Discovery of a Novel Small-Molecule Binder                        | Frank McCormick, PhD<br>Professor of the UCSF Helen Diller Family Comprehensive Cancer Center                               |
| 27-Feb | 09:00 - 10:00 AM | Innovative Approaches in Clinical Trials | Keynote Presentation: Fully Automated IHC Multiplexing: Techniques and Assay Development   | Mark Hellewell, PhD<br>DISCOVERY Reagent & Training Lead, Companion Diagnostics (CDx) & DISCOVERY, Roche Tissue Diagnostics |
| 27-Feb | 10:30 - 11:30 AM | Innovative Approaches in Clinical Trials | Developing Precision Combination Therapies to Overcome Evolution of Therapeutic Resistance   | Khyati Shah, PhD<br>Post Doctoral Research Scholar at University of California, San Francisco                               |
| 27-Feb | 10:30 - 11:30 AM | Novel Strategies for Drug Discovery      | In Vivo Surgical Models for Drug Discovery: Hidden Pitfalls and Their Avoidance  | Matthew Flegal, BS, SRS<br>Senior Manager InVivo Sciences, Charles River  |
| 27-Feb | 10:30 - 11:30 AM | Novel Strategies for Drug Discovery      | Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery  | G. Thomas Caltagirone, PhD<br>President & CEO, Aptagen, LLC   |

|        |                           |   |  |   |
|--------|---------------------------|---|--|---|
| 27-Feb | 10:30<br>-<br>11:30<br>AM | Effective<br>Tools for<br>Drug<br>Development     | The Current State-of-the-Art Tissue Expression Analysis Platform for Detection & Quantification of Target & Biomarker mRNAs, Splice Variants and Mutations in Preclinical & Clinical Tissues | Christopher Bunker, PhD<br>Vice President of Business Development, Advanced Cell Diagnostics  |
| 27-Feb | 12:00<br>-<br>01:00<br>PM | Effective<br>Tools for<br>Drug<br>Development     | Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma   | Sarah Warren, PhD<br>Senior Director of Advanced Applications, NanoString Technologies  |
| 27-Feb | 12:00<br>-<br>01:00<br>PM | Novel<br>Strategies<br>for Drug<br>Discovery      | Nanostructured Molecularly Imprinted Polymers: Robust, Stable and Selective Alternatives to Antibodies   | Adrian Kinkaid<br>CEO, MIP Diagnostics  |
| 27-Feb | 12:00<br>-<br>01:00<br>PM | Innovative<br>Approaches<br>in Clinical<br>Trials | Studies on Malignancies With a Novel Proliferation Biomarker   | Martin Shaw<br>Business Development Manager at AroCell AB   |
| 27-Feb | 12:00<br>-<br>01:00<br>PM | Novel<br>Strategies<br>for Drug<br>Discovery      | Why Pain Control Is Good Science-The Scientific Rationale  | Marcel Perret-Gentil, DVM, MS<br>University Veterinarian & Director, Laboratory Animal Resources Center, University of Texas at San Antonio |
| 27-Feb | 01:30<br>-<br>02:30<br>PM | Effective<br>Tools for<br>Drug<br>Development     | Advanced Liver Tissue Model for Improved in Vitro Prediction   | Matthew K. Shipton, MS<br>Chief Operating Officer, HµREL Corporation  |
| 27-Feb | 01:30<br>-<br>02:30<br>PM | Effective<br>Tools for<br>Drug<br>Development     | Advances in Three-Dimensional Cell Culture in Drug Research and Discovery  | Richard Eglen, PhD<br>Vice President and General Manager, Corning Life Sciences   |
| 27-Feb | 01:30<br>-<br>02:30<br>PM | Innovative<br>Approaches<br>in Clinical<br>Trials | Application of Pharmacogenomics During Clinical Trials   | Annette Gilchrist, PhD<br>Associate-Professor, Pharmaceutical Sciences, Midwestern University   |
| 27-Feb | 01:30<br>-<br>02:30<br>PM | Novel<br>Strategies<br>for Drug<br>Discovery      | Aptamers in Drug Development: From Biomarker Discovery to Targeted Drug Delivery to Small Molecule Drug Detection  | Bill Jackson, PhD<br>Founder and Chief Scientist, Base Pair Biotechnologies   |
| 27-Feb | 01:30<br>-<br>02:30<br>PM | Effective<br>Tools for<br>Drug<br>Development     | Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSight™ Oncology 500  | Phillip Febbo, MD<br>Chief Medical Officer, Illumina, Inc.<br>Maude Champagne<br>Clinical Oncology Marketing, Illumina, Inc.                |

|        |                           |   |  |  |
|--------|---------------------------|---|--|--|
| 27-Feb | 03:00<br>-<br>04:00<br>PM | Effective<br>Tools for<br>Drug<br>Development     | Automation Meets Cell Separation: Primary Cells for Drug<br>Discovery Assays | Lotta Raty<br>Global Product Manager Cell Separation, Miltenyi Biotec  |
| 27-Feb | 03:00<br>-<br>04:00<br>PM | Innovative<br>Approaches<br>in Clinical<br>Trials | BASKET Trials: Biomarker Driven Drug Development                             | Shivaani Kummar, MD, FACP<br>Professor of Medicine (Oncology) and of Radiology<br>(Molecular Imaging Program at Stanford), Director Phase I<br>Clinical Research, Director, Translational Oncology<br>Program, Stanford University |
| 27-Feb | 03:00<br>-<br>04:00<br>PM | Effective<br>Tools for<br>Drug<br>Development     | Do You Have the Gut-on-a-Chip?   | Elena Naumovska, PhD<br>Scientist of Application Development, Mimetas - The Organ<br>on a Chip Company   |
| 27-Feb | 03:00<br>-<br>04:00<br>PM | Novel<br>Strategies<br>for Drug<br>Discovery      | Targeted Cancer Chemotherapy: Developing NextGen<br>Antibody-Drug Conjugates | Jagath Reddy Junutula, PhD<br>Senior Vice President, Research & Development, ModMab<br>Therapeutics, Inc.  |